|
Post by stevil on Nov 10, 2015 15:36:56 GMT -5
Patryn, If it come to that the IP will go to bond holders and not stock holders. No way Mann sells before that. His heirs might see it differently though and could be amiable to a deal before it gets to the bond holder vs shareholder stage of things. We have to trust management to tell us that there are no problems with Sanofi. The same guys who told us financing was good and that sales and partnerships for TS etc were imminent. Didn't Mann come out and say that he isn't leaving his estate to his offspring? Only like 10% of it or something like that? I'm hoping he has very detailed instructions on how his money will be used and that most of it will go to ensuring the survival of MNKD as long as needed.
|
|
|
Post by stevil on Nov 10, 2015 15:34:48 GMT -5
Derek: Thanks for the positive post. I agree with your comments. Although the CC wasn't the best in many ways, several folks have pointed out that aside from the dilution, eroded share price, and piling on by analysts; nothing fundamental has changed. If MNKD was a good investment based on the potential of Afrezza and Technosphere a year ago, it remains a good investment today. To a certain extent, perhaps, we are victims of our own optimistic expectations for growth and our underestimation of the significance of the barriers. As a result, MNKD today is the Rodney Dangerfield of Wall Street, so it helps to keep things in perspective. The stock is on sale right now. I never expected to pick some up for under $2.50; but thanks Wall Street. These shares will join the others in my portfolio that are not available for shorting, as I don't support the self-defeating notion of lending my shares. I'll be patiently awaiting some additional good news... GLTAL Chris-C Chris-C, You're a good poster so I hope you don't mind me replying to you. Just want to point out that if MNKD was a good investment based on the potential of Afrezza and TS that we should see some indication of that. I'm not saying that it's a bad investment. It is a bad investment RIGHT NOW. And while many, many drugs have taken off after their first year on the market, the likelihood of success is lower now than it was a year ago. Add to that the impending cash flow problems and your logic isn't fully sound. The longer this drags out without truly good news, the less likely this will end up being a good investment. Time is not on our side at the moment. We have to establish ourselves before time can be our ally. That hasn't happened yet.
|
|
|
Post by stevil on Nov 10, 2015 15:26:16 GMT -5
It's hard, but it'd be nice if we could have a FAQ post pinned to the top so all this stuff doesn't get hashed and re-hashed. Then, as more questions arise, we can add to it. It'd be an easy way to point people to, well, the most frequently asked questions...
|
|
|
Post by stevil on Nov 10, 2015 15:23:46 GMT -5
patryn, Dude, I like your posts. You're respectful, knowledgeable, and you communicate well. Thanks for being a balanced long that doesn't get their jimmies rustled by pointed questions or assertions.
|
|
|
Post by stevil on Nov 10, 2015 15:17:22 GMT -5
But you said yourself earlier you have no horse in this race. You bowed out so your money isn't at stake, you just really violently want to see MNKD succeed and are vociferously attacking the company, the management, and the marketing partner in order to do so? At that time I didn't have a horse in the race, I do have a stake in it now, in a moment of of weakness I got back in at $3.30. Can any of you agree that if mnkd were successful (making sales and money) the shorts would not be an issue? Again, the shorts are not the problem they are the result of a problem! jury, It truly is both. If the shorts didn't attack MNKD, we wouldn't have to dilute and extend to TASE. Maybe that was part of the plan before they "needed" to and maybe plans fell through with TEVA on a TS application. But MNKD probably should be trading higher than it is. And if it did, BK wouldn't be such a concern. Ultimately, you're right though. If we had more horses in the stable than our colt Afrezza, shorts wouldn't have safe haven. Hopefully if BK ever becomes a reality, a buyout would still leave the shorts with less than they hope for. Not sure how they're able to make money paying close to 50% interest though. It's nuts...
|
|
|
Post by stevil on Nov 9, 2015 21:31:15 GMT -5
effort and results. And I referenced Toujeo. A lot of coverage has to do with contracts. How much the supplier is willing to sell their product for. If SNY doesn't feel they're getting compensated properly, it's all or nothing. So someone has to budge. It's a delicate dance, no doubt, but they don't seem too motivated to get Afrezza covered. Insurance companies want to cover cheaper drugs. And they want to cover drugs in general. The more coverage they have, the more attractive they are to their potential customers. The ball is in SNY's court here. It's not my job to make the call on how much Afrezza is worth for reimbursement, but I can tell you with certainty that it should be covered by now. It's not any newer of a medication than Toujeo is. It's human insulin. Sure, it's inhaled, but insurance companies don't care about that. If there are any complications due to the inhaled particles, MNKD will get sued and will be responsible for any damages. The FDA has already approved the drug. It's all hinging on contractual agreements over reimbursement. Conveniently, I also worked in revenue at a hospital for 2 years, so I'm somewhat familiar with insurance contracts. I could be wrong, but that's my understanding off the knowledge and experience I have... Lot of hate coming your way.... I think it is pretty undue and won't be participating. Personal attacks are petty and those on the internet more so. I have to disagree with what I bolded in your quote. Afrezza certainly is newer medication than Toujeo. As has been stated here and on every MNKD message board for the past year or so, Toujeo is just Lantus, a drug that is very well understood by patients, prescribers, and payers. I, and those I find to be informed, think there are a number of unique characteristics of Afrezza that concern these three groups and require serious education efforts for successful uptake. This has been and continues to be where Sanofi is putting their resources for Afrezza. They were able to be more effective, on face value, with Toujeo partly because of the incentive in protecting the basal franchise and partly because less barriers stood in their way. Thanks for your words cathode. I'll be signing off tonight after this. I always viewed this as a message board. People share what they know and bounce ideas off of each other. But it appears either the majority, or very vocal minority don't want me here. So I'll just keep gleaning information from the peppy's and lakers's and mnholdem's of the site and keep the popcorn bowl full I appreciate someone disagreeing with me, but I won't get back into it with you... Kinda tired and ready to call it a night
|
|
|
Post by stevil on Nov 9, 2015 21:27:10 GMT -5
effort and results. And I referenced Toujeo. A lot of coverage has to do with contracts. How much the supplier is willing to sell their product for. If SNY doesn't feel they're getting compensated properly, it's all or nothing. So someone has to budge. It's a delicate dance, no doubt, but they don't seem too motivated to get Afrezza covered. Insurance companies want to cover cheaper drugs. And they want to cover drugs in general. The more coverage they have, the more attractive they are to their potential customers. The ball is in SNY's court here. It's not my job to make the call on how much Afrezza is worth for reimbursement, but I can tell you with certainty that it should be covered by now. It's not any newer of a medication than Toujeo is. It's human insulin. Sure, it's inhaled, but insurance companies don't care about that. If there are any complications due to the inhaled particles, MNKD will get sued and will be responsible for any damages. The FDA has already approved the drug. It's all hinging on contractual agreements over reimbursement. Conveniently, I also worked in revenue at a hospital for 2 years, so I'm somewhat familiar with insurance contracts. I could be wrong, but that's my understanding off the knowledge and experience I have... It seems like Toujeo having clinical trials showing superiority to an already widely used Lantus, makes that a bit of a stretch to set as an expectation... but ok. It stills seems like you've got some non public information or mind reading abilities (above bold). Maybe SNY and MNKD have more faith than you in Afrezza being able to command a high price and still get decent coverage in time. Remember, SNY would be motivated to maximize the franchise value, not necessarily strike deals for expediency. I would have every expectation that SNY is expending great effort on formulary issue... though I'll be first to say that is an expectation with no non public information backing it up. No non public information here. Again, I form an opinion off of what is known. I read the tea leaves. Why hasn't SNY bought into MNKD if their faith is so high? Why do they not endorse Afrezza more in their presentations? As Blindhog has shown, SNY is already in trouble with another drug for doing the bare minimum (or actually less than what was contractually agreed upon) so they have a reputation of sand bagging drugs. SNY has a different CEO than the one who approved of the Afrezza deal. I could be wrong, but yes, their motivation seems suspect at best right now. It appears SNY is finally budging more on price because they're realizing something is better than nothing. And while time isn't all that important to SNY, their supplier in MNKD doesn't have more than 2 years left right now on the books. They need to help them out and make a deal. I'm not a businessman, but we don't have the leverage right now to make great deals. Al has worked his magic in the past, but we just need a steady stream of revenue to fund the "embarrassment of riches". We can't put all our eggs in the Afrezza basket. That's what's so dangerous about MNKD's situation right now. We need more revenue streams than just one, especially when that one isn't panning out the way it was expected.
|
|
|
Post by stevil on Nov 9, 2015 21:03:45 GMT -5
effort and results.
And I referenced Toujeo.
A lot of coverage has to do with contracts. How much the supplier is willing to sell their product for. If SNY doesn't feel they're getting compensated properly, it's all or nothing. So someone has to budge. It's a delicate dance, no doubt, but they don't seem too motivated to get Afrezza covered.
Insurance companies want to cover cheaper drugs. And they want to cover drugs in general. The more coverage they have, the more attractive they are to their potential customers. The ball is in SNY's court here. It's not my job to make the call on how much Afrezza is worth for reimbursement, but I can tell you with certainty that it should be covered by now. It's not any newer of a medication than Toujeo is. It's human insulin. Sure, it's inhaled, but insurance companies don't care about that. If there are any complications due to the inhaled particles, MNKD will get sued and will be responsible for any damages. The FDA has already approved the drug. It's all hinging on contractual agreements over reimbursement. Conveniently, I also worked in revenue at a hospital for 2 years, so I'm somewhat familiar with insurance contracts.
I could be wrong, but that's my understanding off the knowledge and experience I have...
|
|
|
Post by stevil on Nov 9, 2015 20:45:38 GMT -5
if you were on a roll you'd probably be good with cream cheese and lox. People have disturbed you? You give up your own power and conviction too easily. Is that you in that avatar or are you just using it as a symbol of your self? For you to assess me and who I am with my own conviction you must have some kind of credentials. You know "my friend" sometimes it's either "it iz or it ain't". I am suspect by posters like you who show up today as a first time poster with some very strong opinions. If you are fearful sell your shares and move on. Everyone makes mistakes and if you have come to the conclusion that buying MNKD has been that for you; then I wish you well along the way. If it makes you feel better, I have taken a few credit hours of psychiatry, so that should count for something. And yes, that is me. And no, I'm not a first time poster. I'm just more active today than usual because it's been extremely hard to get back into the swing of things after a week break. I finally got used to being relaxed and now I'm having to go full stress again. Takes me a while to acclimate. But no, people haven't disturbed me. I just care more than I should. And I assert myself where I don't belong when I care. Probably why I went into medicine. I have a savior complex...
|
|
|
Post by stevil on Nov 9, 2015 20:40:18 GMT -5
I appreciate that. And I'll be going back into my hole soon. I just got back from a week off and I'm finding it's hard to get the wheels turning again. I won't have time to post much again soon, probably better for everyone ha. I appreciate your sentiments. And no hard feelings. I'm learning it's better to agree to disagree with 90% of this board. Just hope I'm wrong! Stevil, hope you don't mind my asking, but are you a physician? Couldn't help but notice your "whitecoat" Cheers, Derek Not yet. Student doctor. Almost there!
|
|
|
Post by stevil on Nov 9, 2015 20:22:54 GMT -5
No worries Stevil, and glad to hear you're making money in oil. I'm glad you post here, glad you enjoy it, but personally will no longer post responses to what you may have to say; not out of disrespect, but I've "been here, done this" with other soft-bashers and frankly, am quite tired of it. I appreciate that. And I'll be going back into my hole soon. I just got back from a week off and I'm finding it's hard to get the wheels turning again. I won't have time to post much again soon, probably better for everyone ha. I appreciate your sentiments. And no hard feelings. I'm learning it's better to agree to disagree with 90% of this board. Just hope I'm wrong!
|
|
|
Post by stevil on Nov 9, 2015 20:20:27 GMT -5
I think you are a very funny man. yeah. the sky is falling. People have gotten me revved up today. I'm on a roll... You're one of the biggest pumpers on the board though so I'll play. What does a company do if they have no money left to run it? Hakan/Matt have said no TS deals for 2-5 years. They just said that we have enough cash til 2017. The sky isn't falling, but would you prefer the bottom is falling out analogy better? You can't see the forest through the trees my friend. We are not in good shape right now.
|
|
|
Post by stevil on Nov 9, 2015 20:14:47 GMT -5
Hard to say how much more SNY could do if they tried, but their marketing and insurance efforts have been subpar. Look no further than Toujeo. When they have a desire to get something done, they get it done. SNY is just as much a problem as our management.
There's no doubt in my mind, though, that the script count would be a multiple of what it is now if SNY was dedicated to properly advertising this product. And as some have stated on here before, hire an Apple consultant and make the dreamboat hip and cool. The younger generations are going to be the biggest adopters of Afrezza.
|
|
|
Post by stevil on Nov 9, 2015 20:01:12 GMT -5
Thank you for replying Stevil. No one here dislikes you, or at least I don't. How can someone who holds 25K shares, get so down on the company? You stated that you're underwater on this. Why do you try to bring it down further then? You're in med school, yet put a substantial amount of cash into MNKD, now struggling as a result, but you still post neg on it? Makes no sense to me, but whatever. Aloha. I don't try to bring it down further. Can you please point me to those posts? I'm not the CEO of the company. Me being one person isn't going to bring the company down. While many on here have shared that they're happy to be contributing to mankind (small m, one n), we're not here for charity. We're here to invest in a company and receive a positive return on our investment. Many here thought they'd get rich quick and easy on this company. I was guilty of that also when I first invested. But along with Al, Hakan, Matt, and probably everyone else not a short, we're all learning the hard way about why this was plagued with so many roadblocks and how hard they are to overcome. So no, my mission isn't to drive the share price down further. I've stated publicly that my meager holding will stay with me. I'm going down with the ship unless BK is imminent and inevitable. My mission is to be the yin to the yang on this board. To balance out the pumpers and to temper expectations so more people don't keep dumping more money into this stock. There are better options right now. I've made 20% alone in the past month in one of my oil refinery stocks. MNKD could be a good investment again some day. Today is not that day. I can't fix this company. That's management's job. I'll buy more shares and offer my support once they show me it's a good investment.
|
|
|
Post by stevil on Nov 9, 2015 19:51:57 GMT -5
Lakers,
Did you ever come out with the big news you said was coming soon?
|
|